Pressure BioSciences, Inc.'s next confirmed earnings release is scheduled for November 24, 2026.
| Earnings Date | 11/24/2026 |
As of June 30, 2024, Pressure BioSciences, Inc. has 54.04M shares outstanding.
| Shares Outstanding | 54.04M |
As of June 30, 2024, Pressure BioSciences, Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -78.42, indicating conservative leverage, while an interest coverage ratio of -0.54 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.02 |
| Debt / Equity | -78.42 |
| Debt / EBITDA | -3.66 |
| Interest Coverage | -0.54 |
These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -718.28, reflecting losses generated across the asset base. The company generates approximately 92,086.71 in revenue per employee across its workforce of 16.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.14 indicates how many times Pressure BioSciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -718.28 |
| Revenue Per Employee | 92,086.71 |
| Employee Count | 16.25 |
| Inventory Turnover | 2.14 |
As of the close on November 13, 2026, Pressure BioSciences, Inc.'s stock has declined approximately 83.33% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| 52-Week Price Change | -83.33% |
Over the twelve months ended June 30, 2024, Pressure BioSciences, Inc. generated 1.50M in revenue and converted that into -30.72M in net income, yielding earnings per share of -0.83. EBITDA reached -7.98M, while operating income came in at -8.20M.
| Revenue | 1.50M |
| Gross Profit | 322,584.00 |
| Operating Income | -8.20M |
| Pretax Income | -30.72M |
| Net Income | -30.72M |
| EBITDA | -7.98M |
| EBIT | -8.20M |
| Earnings Per Share (EPS) | -0.83 |
As of June 30, 2024, Pressure BioSciences, Inc. holds 14,253.00 in cash and equivalents against 29.19M in total debt, resulting in a net debt position of 28.61M. Total book value stands at -37.23M, with working capital of -42.70M providing operational flexibility.
| Cash & Cash Equivalents | 14,253.00 |
| Total Debt | 29.19M |
| Net Debt | 28.61M |
| Equity (Book Value) | -37.23M |
| Book Value Per Share | -0.69 |
| Working Capital | -42.70M |
Pressure BioSciences, Inc. produced -4.43M in operating cash flow over the twelve months ended June 30, 2024. After subtracting -4,495.00 in capital expenditures, free cash flow totaled -4.43M - equivalent to -0.12 per share.
| Operating Cash Flow | -4.43M |
| Capital Expenditures | -4,495.00 |
| Free Cash Flow | -4.43M |
| FCF Per Share | -0.12 |
Over the twelve months ended June 30, 2024, Pressure BioSciences, Inc. posted a gross margin of 21.56, reflecting its pricing power and cost economics. The operating margin of -547.79 and net profit margin of -2,053.23 provide insight into operational efficiency.
| Gross Margin | 21.56 |
| Operating Margin | -547.79 |
| Pretax Margin | -2,053.23 |
| Profit Margin | -2,053.23 |
| EBITDA Margin | -532.97 |
These figures cover the twelve months ended June 30, 2024. The dividend payout ratio of 7.60 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.
| Payout Ratio | 7.60 |
Pressure BioSciences, Inc.'s most recent stock split took place on June 5, 2017 with a 30:1 split ratio.
| Last Split Date | 6/5/2017 |
| Split Ratio | 30:1 |